SUNNYVALE, Calif., Oct. 14 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, today announced that the first CyberKnife Robotic Radiosurgery System in Czech Republic is now treating cancer patients at the University Hospital of Ostrava (UHO) Clinic of Oncology.
The renowned academic center has created a state-of-the-art oncology department with the addition of the CyberKnife System, which is housed in a new dedicated building. With this acquisition, the UHO is now able to significantly expand its therapeutic options by delivering high doses of radiation very precisely in only a few sessions. Their clinical program aims at treating mainly extracranial indications including lung, liver and prostate.
“With the addition of the CyberKnife System to our Radiation Oncology department, we are now able to use full body radiosurgery to target tumors that cannot be easily treated with traditional surgical techniques because of their location, number, size, shape or proximity to vital tissues or organs, or because of the age or health of the patient,” said David Feltl, M.D., Ph.D., MBA, Head of the Oncology Clinic at the UHO. “The intelligent robotics enables us to deliver radiation doses that conform closely to the shape of the tumor. This allows for precise targeting of a tumor, while at the same time minimizes damage to surrounding healthy tissue.”
“We are very pleased to see the benefits of whole body radiosurgery expand into Czech Republic,” said Vittorio Puppo, General Manager, Accuray EIMEA (Europe, India, Middle East and Africa). “This new installation paves the way for greater patient access to CyberKnife radiosurgery, thereby providing an additional treatment option to patients who may not have had other options until now.”
About Ostrava University Hospital’s Oncology Clinic
Opened in October 1950, the Oncology Centre of UHO is the first Czech University hospital accredited by the Joint Commission International (JCI). It ranks among the top facilities in Eastern and Central Europe and guarantees patients from a wide region state-of-the-art treatment adhering to world standards. Additionally, it is a part of a network of thirteen specialized oncology centres in the Czech Republic and is the largest oncology department in the Moravian-Silesian Region. The hospital is also the Czech leader in image-guided radiation therapy (IGRT) and has extensive head and neck and prostate programs. The center uses the latest technologies, including two linear accelerators with highly energetic photons and accelerated electrons, virtual simulator, brachytherapy with high dose input and features teams of top experts. Approximately 4,500 adult patients with all types of malignant tumors are treated with non surgical methods each year at UHO. For more information, please visit http://cyberknife.fno.cz/en
About the CyberKnife® Robotic Radiosurgery System
The CyberKnife Robotic Radiosurgery System is the world’s only robotic radiosurgery system designed to treat tumors anywhere in the body non-invasively. Using continual image guidance technology and computer controlled robotic mobility, the CyberKnife System automatically tracks, detects and corrects for tumor and patient movement in real-time throughout the treatment. This enables the CyberKnife System to deliver high-dose radiation with pinpoint precision, which minimizes damage to surrounding healthy tissue and eliminates the need for invasive head or body stabilization frames.
About Accuray
Accuray Incorporated (Nasdaq: ARAY), based in Sunnyvale, Calif., is a global leader in the field of radiosurgery dedicated to providing an improved quality of life and a non-surgical treatment option for those diagnosed with cancer. Accuray develops and markets the CyberKnife Robotic Radiosurgery System, which extends the benefits of radiosurgery to include extracranial tumors, including those in the spine, lung, prostate, liver and pancreas. To date, the CyberKnife System has been used to deliver more than 100,000 treatments worldwide and more than 206 systems have been installed in leading hospitals in the Americas, Europe and Asia. For more information, please visit www.accuray.com.
Safe Harbor Statement
The foregoing may contain certain forward-looking statements that involve risks and uncertainties, including uncertainties associated with the medical device industry. Except for the historical information contained herein, the matters set forth in this press release, including statements relating to clinical applications, clinical acceptance, clinical benefits, clinical publications, and clinical results are forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements speak only as of the date the statements are made and are based on information available at the time those statements are made and/or management’s good faith belief as of that time with respect to future events. You should not put undue reliance on any forward-looking statements. Important factors that could cause actual performance and results to differ materially from the forward-looking statements we make include: market acceptance of products; competing products, the combination of our products with complementary technology; and other risks detailed from time to time under the heading “Risk Factors” in our report on Form 10-K for the 2010 fiscal year which has been filed with the Securities and Exchange Commission on August 31, 2010. The Company’s actual results of operations may differ significantly from those contemplated by such forward-looking statements as a result of these and other factors. We assume no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws.
SOURCE Accuray Incorporated
